Wells Fargo & Company Prometheus Biosciences, Inc. Transaction History

Wells Fargo & Company

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$103.46 - $126.29 $1.75 Million - $2.13 Million	16,876 Added 1185.11%	18,300 $1.96 Million
Q4 2022 Feb 13, 2023	SELL	$36.06 - $117.21 $202,116 - $656,962	-5,605 Reduced 79.74%	1,424 $156,000
Q3 2022 Nov 14, 2022	BUY	$28.17 - $59.01 $119,018 - $249,317	4,225 Added 150.68%	7,029 $414,000
Q2 2022 Aug 12, 2022	SELL	$22.39 - $38.94 $129,862 - $225,852	-5,800 Reduced 67.41%	2,804 $79,000
Q1 2022 May 16, 2022	SELL	$30.13 - $50.0 $359,390 - $596,400	-11,928 Reduced 58.09%	8,604 $325,000
Q4 2021 Feb 14, 2022	BUY	$22.28 - $39.54 $113,316 - $201,100	5,086 Added 32.93%	20,532 $812,000
Q3 2021 Nov 15, 2021	BUY	$20.89 - $26.96 $321,141 - $414,456	15,373 Added 21058.9%	15,446 $367,000
Q2 2021 Aug 16, 2021	BUY	$16.8 - $29.65 $1,226 - $2,164	73 New	73 $2,000

29.6K

Ticker RXDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,904,100
Description
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.